Dr Jérôme Galon, Research Director at Inserm, Head of the laboratory of Integrative Cancer Immunology, Paris, France, and Scientific Advisor of IO Biotech presented at ASCO 2016 the very positive results of the international initiative, the Immunoscore® study. The assay was developed to predict the ability of a person’s immune system to fight tumor cells and its performance has already been documented in a number of studies for its ability to predict recurrence in colon cancer.
